invoX Pharma Increases Investment in pHion Therapeutics to Further Develop Next Generation of mRNA V
Investment will enable pHion to progress its lead program into the clinicTransaction builds on invoX’s initial investment in 2021LONDON--(BUSINESS WIRE)--invoX Pharma Limited (“invoX”), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) with an advancing pipeline...